[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-336849-105":59,"doc-detail-336849-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","integrative-identification-of-non-coding-regulatory-regions-driving-metastatic-prostate-cancer-research-summary","Integrative identification of non-coding regulatory regions driving metastatic prostate cancer - research summary","","Large-scale sequencing has been used to map the mutational landscape of the coding genome, but most detected variants lie within non-coding regions. This study presents an integrative computational and experimental framework to identify recurrently mutated non-coding regulatory elements that drive tumor progression. Applied to sequencing data from a large prostate cancer cohort, the framework uses in silico analyses, massively parallel reporter assays, and in vivo CRISPR interference screens to validate metastatic castration-resistant prostate cancer drivers.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/integrative-identification-of-non-coding-regulatory-regions-driving-metastatic-prostate-cancer-research-summary/336849/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/integrative-identification-of-non-coding-regulatory-regions-driving-metastatic-prostate-cancer-research-summary/336849.png","ImageObject",300,407,{"name":92,"@type":93},"Rowan","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address about prostate cancer genomics?","Question",{"text":112,"@type":113},"Most variants occur in non-coding genomic regions, yet systematically identifying which non-coding elements drive tumor progression remains challenging. The study targets recurrent non-coding regulatory drivers in metastatic prostate cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the framework identify and validate non-coding regulatory drivers?",{"text":117,"@type":113},"It combines integrative computational analyses with massively parallel reporter assays and in vivo CRISPR interference screens to validate metastatic castration-resistant prostate cancer drivers.",{"name":119,"@type":110,"acceptedAnswer":120},"What is the significance of the enhancer region GH22I030351?",{"text":121,"@type":113},"The enhancer GH22I030351 acts on a bidirectional promoter that simultaneously modulates expression of SF3A1 and CCDC157, which promote tumor growth in vivo.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},336849,1790663564,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},1099514067415,"https://ap-avatar.wpscdn.com/avatar/100002539d78ffe74a7?x-image-process=image/resize,m_fixed,w_180,h_180&k=1779092875211072502","Author Manuscript Author Manuscript Author Manuscript Author Manuscript  \n\n| | HHS Public Access\u003Cbr>Author manuscript\u003Cbr>Cell Rep. Author manuscript; available in PMC 2024 October 10. |\n| --- | --- |\n\nPublished in final edited form as:  \nCell Rep. 2024 September 24; 43(9): 114764. doi:10.1016/j.celrep.2024.114764 .  \nIntegrative identification of non-coding regulatory regions driving metastatic prostate cancer  \nBrian J. Woo 1,2,3,6,9 , Ruhollah Moussavi-Baygi 1,2,3,9 , Heather Karner1,2,3,6,9 , Mehran Karimzadeh 1,2,3,4,5,6,9 , Hassan Yousefi 1,2,3,6 , Sean Lee 1,2,3,6 , Kristle Garcia 1,2,3 , Tanvi Joshi 1,2,3 , Keyi Yin 1,2,3 , Albertas Navickas 1,2,3 , Luke A. Gilbert 1,2,3,6 , Bo Wang4,5 , Hosseinali Asgharian 1,2,3,7,* , Felix Y. Feng2,3,8,* , Hani Goodarzi 1,2,3,6,7,10,*  \n1 Department of Biochemistry & Biophysics, University of California, San Francisco, San Francisco, CA, USA  \n2 Department of Urology, University of California, San Francisco, San Francisco, CA, USA  \n3 Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA  \n4Vector Institute, Toronto, ON, Canada  \n5 Peter Munk Cardiac Centre, University Health Network, Toronto, ON, Canada  \n6Arc Institute, Palo Alto, CA 94305, USA  \n7Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA  \n8 Department of Radiation Oncology, University of California, San Francisco, San Francisco, CA, USA  \n9These authors contributed equally  \n10Lead contact  \nSUMMARY  \nLarge-scale sequencing efforts have been undertaken to understand the mutational landscape of the coding genome. However, the vast majority of variants occur within non-coding genomic regions. We designed an integrative computational and experimental framework to identify recurrently mutated non-coding regulatory regions that drive tumor progression. Applying this framework to sequencing data from a large prostate cancer patient cohort revealed a large set of candidate  \nThis is an open access article under the CC BY-NC-ND license ([http://creativecommons.org/licenses/by-nc-nd/4.0/](http://creativecommons.org/licenses/by-nc-nd/4.0/)).  \n*[Correspondence: hossein.asgharian@gmail.com](Correspondence: hossein.asgharian@gmail.com) (H.A.), [felix.feng@ucsf.edu](felix.feng@ucsf.edu) (F.Y.F.), [hani.goodarzi@ucsf.edu](hani.goodarzi@ucsf.edu) (H.G.) . AUTHOR CONTRIBUTIONS  \nL.A.G., F.Y.F., and H.G. conceived the study. B.J.W., H.K., H.Y., S.L., K.G., T.J., and K.Y. designed and performed experiments.  \nR.M.-B., M.K., H.A., and H.G. built computational tools of the study and conducted data analysis. H.G., R.M.-B., B.J.W., and M.K. wrote and edited the manuscript. L.A.G., F.Y.F., and H.G. acquired funding for the study.  \nDECLARATION OF INTERESTS  \nThe authors declare no competing interests.  \nSUPPLEMENTAL INFORMATION  \nSupplemental information can be found online at [https://doi.org/10.1016/j.celrep.2024.114764](https://doi.org/10.1016/j.celrep.2024.114764) .  \nAuthor Manuscript Author Manuscript Author Manuscript Author Manuscript  \nWoo et al. Page 2  \ndrivers. We used (1) in silico analyses,(2) massively parallel reporter assays, and (3) in vivo CRISPR interference screens to systematically validate metastatic castration-resistant prostate cancer (mCRPC) drivers. One identified enhancer region, GH22I030351, acts on a bidirectional promoter to simultaneously modulate expression of the U2-associated splicing factor SF3A1 and chromosomal protein CCDC157 . SF3A1 and CCDC157 promote tumor growth in vivo. We nominated a number of transcription factors, notably SOX6, to regulate expression of SF3A1 and CCDC157 . Our integrative approach enables the systematic detection of non-coding regulatory regions that drive human cancers.  \nGraphical Abstract  \nIn brief  \nWoo et al. developed and implemented a computational and experimental platform to identify and characterize non-coding driver regulatory regions in metastatic pros","cbCaio04wMxBVefD","https://ap.wps.com/l/cbCaio04wMxBVefD","pdf",1972957,43,"English","# Summary\n## Integrative computational and experimental framework\n## Validation strategy for non-coding drivers\n## Case example: GH22I030351 enhancer","[{\"question\":\"What problem does the study address about prostate cancer genomics?\",\"answer\":\"Most variants occur in non-coding genomic regions, yet systematically identifying which non-coding elements drive tumor progression remains challenging. The study targets recurrent non-coding regulatory drivers in metastatic prostate cancer.\"},{\"question\":\"How does the framework identify and validate non-coding regulatory drivers?\",\"answer\":\"It combines integrative computational analyses with massively parallel reporter assays and in vivo CRISPR interference screens to validate metastatic castration-resistant prostate cancer drivers.\"},{\"question\":\"What is the significance of the enhancer region GH22I030351?\",\"answer\":\"The enhancer GH22I030351 acts on a bidirectional promoter that simultaneously modulates expression of SF3A1 and CCDC157, which promote tumor growth in vivo.\"}]","Integrative identification of non-coding regulatory regions driving metastatic prostate cancer - research summary | PDF",1790016853,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/074adf92214bb24aa7ae8aeef1c5aa19.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49de4b4ef63d79946b396e3bb40528e7.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f2443d047d4b839e0e1e811b043b977e.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/88a55d255086e6815d3066eca11bd8b6.webp",980,1268,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/cb796e6552b078048a66737fa6e25773.webp",979,1267]